Implants of Tenofovir Alafenamide Could Provide Protection for 6 Months, Study Says
April 12th 2019Subcutaneous implants are 1 promising strategy to address suboptimal adherence to pre-exposure prophylaxis (PrEP) for HIV, and a recent in silico simulation examined pharmacokinetic profiles and safety of tenofovir alafenamide implants.